Strategies in early arthritis management.
Completed
- Conditions
- rheumatoid arthritis, undifferentiated oligo- or polyarthritis
- Registration Number
- NL-OMON25364
- Lead Sponsor
- Prof dr BAC DijkmansVUmc
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 80
Inclusion Criteria
1. Age 18+;
Exclusion Criteria
1. Earlier treatment with disease modifying antirheumatic drugs except hydrxychloroquine;
2. Prednisone use within 3 months;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression of radiographic damage score after 2 years.
- Secondary Outcome Measures
Name Time Method 1. Functional capacity;<br /> 2. Quality of life; <br />3. Disease activity.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are targeted by early arthritis management strategies in NL-OMON25364?
How does the NL-OMON25364 trial compare synthetic DMARDs to biologic therapies for undifferentiated polyarthritis?
Which biomarkers correlate with treatment response in early rheumatoid arthritis patients enrolled in NL-OMON25364?
What adverse event profiles are associated with novel arthritis management protocols in this trial?
Are there combination therapies involving JAK inhibitors or IL-6 antagonists evaluated in NL-OMON25364 for early arthritis?